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Abstract
Background: Health and social care provision for an ageing population is a global priority. Provision for those with
dementia and hip fracture has specific and growing importance. Older people who break their hip are recognised
as exceptionally vulnerable to experiencing confusion (including but not exclusively, dementia and/or delirium and/
or cognitive impairment(s)) before, during or after acute admissions. Older people experiencing hip fracture and
confusion risk serious complications, linked to delayed recovery and higher mortality post-operatively. Specific care
pathways acknowledging the differences in patient presentation and care needs are proposed to improve clinical
and process outcomes.
Methods: This protocol describes a multi-centre, feasibility, cluster-randomised, controlled trial (CRCT) to be undertaken
across ten National Health Service hospital trusts in the UK. The trial will explore the feasibility of undertaking a CRCT
comparing the multicomponent PERFECTED enhanced recovery intervention (PERFECT-ER), which acknowledges the
differences in care needs of confused older patients experiencing hip fracture, with standard care. The trial will also have an
integrated process evaluation to explore how PERFECT-ER is implemented and interacts with the local context. The study
will recruit 400 hip fracture patients identified as experiencing confusion and will also recruit “suitable informants” (individuals
in regular contact with participants who will complete proxy measures). We will also recruit NHS professionals for the
process evaluation. This mixed methods design will produce data to inform a definitive evaluation of the intervention via a
large-scale pragmatic randomised controlled trial (RCT).
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Discussion: The trial will provide a preliminary estimate of potential efficacy of PERFECT-ER versus standard care; assess
service delivery variation, inform primary and secondary outcome selection, generate estimates of recruitment and retention
rates, data collection difficulties, and completeness of outcome data and provide an indication of potential economic
benefits. The process evaluation will enhance knowledge of implementation delivery and receipt.
Trial registration: ISRCTN, 99336264. Registered on 5 September 2016.
Keywords: Dementia, Hip fracture, Feasibility, Acute care, Hospital, Service improvement
Background
Hip fracture is one of the commonest orthopaedic injur-
ies [1]. It is estimated that more than 1.2 million individ-
uals worldwide suffer hip fracture annually [2], a total
expected to surpass 6 million by the year 2050 [1]. Hip
fracture has a substantial impact on the health, wellbeing
and independence of patients and their families. It also
generates high costs for health and social care systems;
for example the impact on the National Health Service
(NHS) in the UK is estimated at £2 billion per annum
[3]. In the first 12 months post-fracture, patients are at
increased risk of functional decline, admission to long-
term care institutions and higher mortality rates [4].
Over 40% of people with hip fracture have dementia
or cognitive impairment [5]. This can impact on re-
habilitation and recovery following hip surgery [5, 6].
Pre-existing “confusion” (including, but not exclusively,
dementia and/or delirium) has been associated with
greater risk of postoperative complications such as pres-
sure ulcers and chest infections [4]. People who are con-
fused may also find it more difficult to express pain and
discomfort, making the assessment of these conditions
more challenging [6]. The risk of confusion is of particu-
lar concern for people admitted to acute setting with
prior memory difficulties and can have a more serious
impact on their daily life [7, 8].
Confusion can compromise a patient’s ability to engage
and progress with postoperative hip fracture rehabilita-
tion. There is currently little evidence to guide practi-
tioners to choose the care and rehabilitation
interventions that will achieve the best outcomes for
confused older people [9]. This has led to calls for
patients with hip fracture experiencing confusion to have
a specific treatment pathway, to acknowledge the differ-
ences in presentation and care needs.
A specified process of “enhanced recovery” has been
used in UK health services since the early 2000s [10].
Enhanced recovery pathways (ERP) are becoming stand-
ard practice for many elective surgical operations [11].
Enhanced recovery practices rely upon integrated, multi-
modal, evidence-based approaches that aim to enable
patients to recover and leave hospital sooner after sur-
gery. Whilst embedded in many elective practices, it has
not been standard to take an enhanced recovery
approach in treating acute hip fracture.
The National Hip Fracture Database (NHFD) was de-
veloped and launched by the Royal College of Physicians
as part of their “Falls and Fragility Fracture programme”
[12]. The NHFD is web-based and requires data to be
entered on auditable aspects of the care delivered to
every patient with hip fracture across Northern Ireland,
Wales and England. It integrates nationally agreed stan-
dards for the management of patients aged 60 years or
older as set by the British Orthopaedic Association,
British Geriatrics Society and National Institute for
Health and Care Excellence (NICE) clinical guideline.
NHFD data support a system of “payment by results” in
England and Wales known as the Best Practice Tariff
(BPT). Findings on the impact of the NHFD and BPT
have demonstrated improved outcomes via the co-
management of patients by consultant geriatrician and
orthopaedic surgeon [13], a reduction in mortality rates
[14] and decreased time to surgery [15]. Although not
delineated in relation to how care could/should be deliv-
ered to patients with hip fracture experiencing confusion,
these studies do suggest that multicomponent care inter-
ventions can improve a range of patient and clinical out-
comes. Internationally, the picture is similar. Interventions
show potential but do not provide guidance on the best
methods of delivering care to older confused patients with
hip fracture [16–19]. Hence, answers to core questions
remain relating to the best types of preoperative, postoper-
ative and rehabilitation approaches for hip fracture care
for patients experiencing confusion, and how such path-
ways can be delivered.
To address this global priority, a multicomponent inter-
vention was developed as part of the “Peri-operative
enhanced recovery hip fracture care of patients with demen-
tia” (PERFECTED) research programme. PERFECTED
encompassed several iterative and sequential sub-studies
(“Care delivery in acute hospital settings: an observational
study” UKCRN ID 16998, REC: 14/EM/1020, “Caring for pa-
tients with hip fracture and memory difficulties” (UKCRN
ID 18281, REC: 15/EE/0007) and “Implementing the opti-
misation of hospital care delivery to older adults by NHS
staff via action research methodology” (UKCRN ID 179797,
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REC: 15/SC/0294)). The PERFECTED enhanced recovery
intervention (henceforth PERFECT-ER) was developed in
accordance with the Medical Research Council (MRC)
framework for complex interventions [20, 21] and aims to
enhance recovery of patients with hip fracture experiencing
confusion (including presumed dementia and/or other
cognitive impairments such as delirium). The objective of
the current study is to explore potential efficacy and cost-
effectiveness of PERFECT-ER versus standard care in older
patients with hip fracture who are experiencing confusion.
The study’s ultimate objective is to inform a definitive evalu-
ation of PERFECT-ER via a large-scale pragmatic rando-
mised controlled trial (RCT). The protocol format is guided
by the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist (Additional file 1) and the
Consolidated Standards of Reporting Trials (CONSORT) ex-
tension to cluster-randomized trials [22, 23].
Methods
Aims and objectives
The aim of this study is to test trial and intervention
feasibility to inform a definitive trial. The current study
therefore has the following research objectives:
1. Generate preliminary estimates of potential efficacy
of the PERFECT-ER versus standard care at 1, 3 and
6 months postoperatively
2. Assess service delivery variation between control and
active wards
3. Inform primary and secondary outcome selection
4. Generate estimates of recruitment and retention
rates, data collection difficulties, and completeness
of outcome and costs data
5. Estimate the intra-class correlation coefficients for
efficacy endpoints in order to inform sample size
calculations for a later study
6. Assess potential intervention effectiveness
7. Assess the resource use, costs and outcomes
associated with the intervention
8. Collect data to inform a comprehensive process
evaluation
Design
This multicentre, interventional, feasibility study is an
open trial, which will be cluster randomised. In line with
MRC guidance for complex interventions [20, 21], an
integrated multimethod multi-perspective (patients, suit-
able informants (defined as individuals with regular
contact who are prepared to complete proxy measures)
and NHS professionals) process evaluation will be con-
ducted. This will explore variations in implementation
fidelity, dose and reach. Trial hospitals will be rando-
mised to active or control arm within geographical
region using a simple randomisation process. An ad hoc
programme will be written in SAS to carry out this
procedure (see Fig. 1 Randomization overview). The na-
ture of PERFECT-ER means that patients, suitable infor-
mants and staff delivering treatments cannot be masked
to the trial arm. Accordingly, this is an open unblinded
trial. Statistical analysis will be undertaken by a
subgroup-blind approach, blinded to trial arm and
cluster.
Setting
The study will be conducted in acute hospital wards in
ten NHS hospitals located in five different UK regions
(England: four regions, eight hospitals; Scotland: one
region, two hospitals) to which individuals who sustain
proximal hip fracture are admitted. Each hospital will
contribute one study ward. The unit of randomisation is
the cluster, in this case, the hospital site. The following
site inclusion and exclusion criteria have been identified.
Site inclusion criteria:
Fig. 1 Randomisation overview; we will recruit ten hospitals across five separate geographical UK regions. One hospital per region will be
randomised to active or control arm
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 Sites have an average monthly admission of at least
12 individuals who sustain proximal hip fracture
requiring an operation and have a preoperative
Abbreviated Mental Test Score (AMTS) ≤8
(England) or a 4AT ≥1 (Scotland) in the last 12
available calendar months
 Sites are able to provide the PERFECTED trial team
with contextual ward level data (comprising BPT
scores, number of falls, pressure ulcers, deaths and
safeguarding incidents) in the last 12 available
calendar months
Site exclusion criteria: sites that have participated in
the “PERFECTED WP2: Implementing optimised hos-
pital care” research programme leading to the develop-
ment and refinement of PERFECT-ER will be excluded.
Participants
Because of the cognitively vulnerable nature of the
patient population, proxy measures will be used along-
side patient-generated measures. Consent will therefore
be sought from patients where possible and from “suit-
able informants” as defined subsequently. The eligibility
criteria for patient participants and suitable informant
participants are as follows.
Patient inclusion criteria:
1. Patient must have had confirmed proximal hip
fracture requiring an operation and be aged ≥
60 years at the time of the operation
2. Patient has a preoperative AMTS ≤8 in England
(including those with zero because of an inability to
answer questions) or a 4AT score ≥1 in Scotland
3. Patient must have a “suitable informant” (e.g.
relative, unpaid or paid carer, care home manager)
who has a minimum of once a month face-to-face
or telephone contact with the patient and is able,
and consents to, provide information on proxy
measures
4. Patient and a suitable informant must be recruited
into the trial within 7 days of the hip fracture
operation
5. Patient must spend a minimum of 5 days on the
study ward
Patient exclusion criteria:
1. Decision taken not to undergo hip surgery
2. Patient not expected to survive beyond 4 weeks
3. Patient already enrolled in a clinical trial of an
investigational medicinal product (CTIMP)
Suitable informant inclusion criteria:
1. Individual has a minimum of once a month face-to-
face or telephone contact with the patient
2. Individual is able, and consents to provide
information on proxy measures
Suitable informant exclusion criteria: Individual not
over 16 years of age.
Intervention
PERFECT-ER is a multicomponent service improvement
intervention with a systematic implementation process.
It comprises of the PERFECT-ER checklist, which syn-
thesizes best practice evidence of hospital-based
dementia care delivery with current best practice
evidence of the admission, preoperative, postoperative,
rehabilitation and discharge management of hip frac-
tures, agents of change (described below) and a model
for change (plan-do-study-act). The checklist, consisting
of patient-level and organizational-level care elements, is
designed to overlay existing hip fracture pathways
highlighting areas to improve care delivery to patients
experiencing confusion. PERFECT-ER has been devel-
oped, piloted and refined in earlier PERFECTED work
packages in partnership with a range of stakeholders in
diverse development sites. As the current paper is
reporting the protocol for a feasibility study the inter-
vention is understandably not yet in the public domain.
Sites allocated to the active arm will be given PERFECT-
ER 3 months before recruitment begins and resourced to
support the implementation of PERFECT-ER using the
NHS Service Improvement (plan-do-study-act) method-
ology [24]. The resource is in the form of an internal
chance agent, known in this study as a Service Improve-
ment Lead (SIL). Following the 3-month implementation
period led by the SIL (and provided that individual active
sites have reached predesignated PERFECT-ER adherence
scores) sites will open to recruitment.
Control arm
Control is treatment as usual. Local practices in each site
will differ. We will collect relevant site profile data
(please see “Site profile data” for details).
Recruitment and consent procedures
Recruitment will commence when individual active sites
have reached predesignated PERFECT-ER adherence
scores. Recruitment will take place over a 10-month
period; participants will be followed for 6 months. A
three-step recruitment process has been guided by our
experiences from previous phases of the PERFECTED
programme, other studies in this area [25, 26] and con-
versations with clinical and academic collaborators:
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1) Research nurses will collaborate with relevant
clinical staff (including the study ward trauma
co-ordinators and key Emergency Department
colleagues) to identify all new hip fracture
admissions and screen for pre-recruitment eligibility
2) Each patient (and where possible their potential
suitable informant) will be approached by a research
nurse who provide them information about the
study as soon as clinically appropriate. During this
initial approach the research nurse will assess the
mental capacity of the patient.
3) The research nurse will approach the patient (where
possible) and identified suitable informant to obtain
informed consent. In England, where a patient is
assessed as lacking capacity, personal or nominated
consultee advice about inclusion will be sought. In
Scotland, where a patient is assessed as lacking
capacity, a welfare guardian, welfare attorney or
nearest relative (henceforth known as a legal
representative) will be sought and asked to consent
in relation to the patient’s participation in the study.
If appropriate and willing, suitable informants can
also be personal consultees (England) or legal
representatives (Scotland).
This three-step process will be closely monitored by
the coordinating centre to identify trends that might be
leading to over-recruitment or under-recruitment from
specific groups. For example, if sites are consenting
purely via personal consultees (England) or legal
representatives (Scotland), monitoring will enable cor-
rective actions and provide information to mitigate
these recruitment trends in any future definitive trial.
A more detailed overview of the recruitment process
is shown in Fig. 2.
Recruiting patients with fluctuating and/or reduced
capacity in England and Scotland
The aims of this trial are incompatible with only enrol-
ling patients with minimal or mild confusion. It is
important to ensure findings are broadly applicable and
able to inform a future definitive trial. Participants who
lack capacity to provide informed consent must be
included. In this situation, the patient’s agreement to
participate will still be obtained to their best level of
understanding (in line with legislative frameworks in
England and Scotland). Where patients in England are
assessed as lacking capacity to make a decision about
their initial or continued involvement with the study, we
will seek personal or nominated consultee advice [27]. In
Scottish trial sites where a patient is assessed not to have
capacity, a legal representative will be sought and asked
to consent in relation to the patient’s participation in the
research [28]. In cases where written informed consent
cannot be obtained, verbal consent can be taken (for
example a patient with extremely poor eyesight or wrist/
arm fractures). However this must be witnessed and fully
documented in the patient’s notes [29]. For suitable
informants in instances where written informed consent
cannot be obtained, verbal consent can be taken over
the telephone but must be witnessed and fully docu-
mented in the patient’s notes [29].
Data collection
This feasibility study will not have a primary outcome.
Instead, this study will inform the selection of the
primary outcome for a potential definitive evaluation of
PERFECT-ER. Because of the complexity and feasibility
nature of this trial, different types of data will be col-
lected from different sources (see Fig. 3). Additional in-
formation about selected outcome measures detailed in
Fig. 3 can be found in Additional file 2.
All outcome assessment timeframes are taken from
the point after a patient returns from surgery. Local re-
search nurses will collect data from patients and their
suitable informants at four time points. Assessment
timeframes are baseline (0–5 days postoperative), follow
up at time 1 (1 month ± 5 days), time 2 (3 months ±
5 days), and time 3 (6 months ± 5 days). Follow-up mea-
sures will be obtained by a local research nurse at the
patient’s place of residence, with suitable informant
follow-up data collected according to pragmatic
arrangements.
We will also collect clinical measures and resource use
data (Fig. 3). We will collect hospital care data (Accident
and Emergency visits, inpatient and day-case admissions,
outpatient appointments) from the clinical records of
the participating NHS Trusts. Data on health and social
care services and unpaid carers used by patients will be
collected at each follow-up time point from the suitable
informants (however only informants who are unpaid
carers will be asked to complete questions on unpaid
carer input). This will allow comparison of hospital-
service use data from both sources. Findings from this
collection and from the process evaluation workstream
will also be used to explore the feasibility of collecting
hospital service-use and cost data from routine sources.
For patients cared for in English trusts, we will also
collect data made available via the NHFD. Findings will
also be used to explore the feasibility of economic data
collection. We will interrogate these data to test for
differences between participating hospitals to inform
later generalisability. We will also draw on these results
to make recommendations for cost data-collection
methods for a definitive trial if indicated, taking into
account research costs, data completeness and reporting
burden experienced by participants.
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Site profile data
To anticipate the expected wide variance in local prac-
tices, sites will complete a ward profiling assessment
(comprising hospital characteristics, study ward charac-
teristics, study ward staff profiling, and patient care pro-
files at organisational and patient level) at baseline, 4, 7
and 10 months following the trial opening. This will
enable any drift from baseline status towards perceived
improvements in service delivery to be monitored across
control and active arms and provide rich contextual data
for the process evaluation.
Process evaluation data
Following MRC guidance for complex interventions
[21], an integrated multimethod, multi-perspective
(patients, suitable informants and NHS professionals)
process evaluation will be conducted. The process evalu-
ation will aim to determine how, and under what cir-
cumstances, PERFECT-ER is implemented in each site
and to examine how, and under what circumstances,
implementing PERFECT-ER impacts on staff practices
and perceptions, resource use, and patient and suitable
informant outcomes. Learning from initial piloting of
PERFECT-ER and its implementation mechanisms (PER-
FECTED WP2: Implementing the optimisation of hos-
pital care delivery to older adults by NHS staff via action
research methodology) will be used to inform proce-
dures for collecting quantitative and qualitative data to
inform the process evaluation. This data set will com-
prise PERFECT-ER checklist scores and SIL-generated
Fig. 2 Recruitment overview; recruitment will take place over a 10-month period with a 6-month follow-up period. All patients entering study
wards will be screened for eligibility. Local research workers will assess patient capacity. Patients interested in participating and assessed as having
capacity will be consented into the study. Patients assessed as not having capacity will be able to take part in line with legislative guidance for
individuals lacking capacity
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reports and action plans. We will also undertake semi-
structured interviews with patients (where appropriate)
and suitable informants with experience of PERFECT-
ER care delivery (25 patients and 25 suitable informants,
5 per population per active site). Interviews with patients
will take place at their place of residence at the time
(hospital, rehabilitation unit, care home or patient’s
home). Locations and mode (face-to-face or telephone)
of semi-structured interviews with suitable informants
will be organised on a case-by-case basis sensitive to in-
dividual preference. Public patient involvement (PPI) is a
central part of the PERFECTED programme. PPI col-
leagues are experts by experience [30]. They will receive
training and assist in co-interviewing of suitable infor-
mants alongside academic researchers on a case-by-case
basis.
Additionally, interviews and focus groups will be held
with NHS professionals involved in ward-level and stra-
tegic implementation of PERFECT-ER. This research will
also explore the economic aspects of caring for people
who are confused and have hip fracture (for instance, to
understand how time is used to provide appropriate care
to this patient group). In addition, we will look at the
feasibility of collecting detailed patient-level costing in-
formation (e.g. patient-specific nursing time, laboratory
tests) from administrative systems in each site, mapping
the availability of information based on correspondence
with hospital administrators/finance officers and a docu-
mentary analysis.
Sample size
The target sample size is 400 patient participants (200
per arm). This will comprise 40 patient participants’ in
10 different sites. As this is a feasibility study, this sam-
ple size was not decided on the basis of efficacy analyses;
rather this is a purposive selection of groups with rele-
vant experience of hip fracture and confusion and ability
to access in the time available. Their data will be used to
estimate the intra-class correlation coefficient for each
outcome measure. Assuming a coefficient of no more
than 0.1, 400 participants from 10 centres should
Fig. 3 Detailed assessment. MMSE, Mini-Mental State Examination;
EQ-5D-EL, EuroQol Five Dimensions Five Levels questionnaire; DEM-
QOL, Dementia Quality of Life; *PERFECT-ER and treatment as usual
continue up until discharge from study ward. Due to differences in
length of stay in the study sites, T1 assessments may take place in
the study site for some participants; **Patients may be discharged
from study ward before or after T1. Measure to be collected at
whenever this point maybe ± five days; ***duration of retrospective
period covered varies by assessment point; ****pre-baseline ordinary
residence; *****If patient is still in acute hospital at thirty days this
will be recorded; ******from hospital patient records, of service use
within site of index hospitalisation; *******extracted from NHFD post
recruitment window closing
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provide a standard error no greater than 0.041, provid-
ing a basis for a definitive trial sample size.
Analysis
Quantitative analysis
Data from the trial will be analysed and reported in
accordance with Consolidated Standards of Reporting
Trials (CONSORT) [23]. An initial estimate of interven-
tion efficacy will be provided using a multi-level model,
with hospital as the highest “cluster” level and an appro-
priate error term depending on the nature of the out-
come of interest. Between-treatment-arm effects will be
estimated with 95% confidence intervals. Analyses will
be on an intention-to-treat basis. There are no plans for
imputing missing data and thus analyses will be on a
complete-case basis only. No subgroup analyses are
planned. In the light of new information, should it be
decided during the course of the trial that a subgroup
analysis is appropriate, this will be recorded in the statis-
tical analysis plan prior to any data analyses. There will
be no formal interim analysis. Deaths, falls, pressure
ulcers, admissions to long-term residential care and safe-
guarding incidents are expected in this patient popula-
tion. These rates will be collected at ward level
throughout the study period. Analysis of recruitment
rates, patient participant (including mortality) and suit-
able informant withdrawal rates will also be reviewed.
Based on the data collected from this study, a formal
sample size calculation will be carried out to inform a
future, definitive trial.
Health and social care costs will be calculated drawing
on the trial data, attaching unit costs from published
sources to quantities of service use [31, 32]. The
additional resource use associated with the intervention
will be examined over the period of the trial by tracking
potential indicators of impact, such as patient time spent
in the anaesthetic room (i.e. this could change because
relatives are encouraged to stay with the patient as part
of the enhanced recovery checklist). SIL salary costs,
on-costs and overheads will be estimated in order calcu-
late their contribution to the costs of participants’ index
hospital stays. Cost-effectiveness analyses will be from
two perspectives - health and social care and societal.
We will analyse outcomes including Bristol Activities for
Daily Living Scale (BADLS) (patients) and quality-
adjusted life-year (QALY) gain (for patients and carers).
Incremental cost-effectiveness ratios will be computed
and cost-effectiveness acceptability curves generated to
examine the probability of cost-effectiveness over a
range of willingness-to-pay thresholds for each outcome.
Multivariate analyses of costs and outcomes appropriate
for the clustered-randomised trial design will control for
centre, baseline outcome measures or costs, and other
confounders. We will compare results of analyses using
societal, patient and carer weights for QALYs generated
from DEMQOL-proxy, and different approaches to valu-
ing unpaid care [32]. Variations in hospital service use
within and between patients (e.g. hospital admissions,
Accident and Emergency visits) will be explored through
latent growth modelling. A sample of Participant Infor-
mation Sheets and Consent Forms can be found in
Additional file 3.
Qualitative analysis
Data such as audio-files not already in a textual form
will be transcribed verbatim and represented as “play
script” transcripts. Once transcribed and formatted these
documents will be imported into the NVivo qualitative
software. Analysis will be conducted iteratively and draw
out emergent themes from the data to explore variations
in implementation fidelity, dose, adaptation and reach.
The Consolidated Framework for Implementation
Research (CFIR) will be used to further guide the ana-
lysis, including the identification of disconfirming data,
points of implementation vulnerability will be examined
to see how these may or may not lead to instances of
breakdowns in the intervention and cases for critical
learning that can inform the definitive trial will be taken
forward [33]. Qualitative data collected pertaining to the
association between costs and resource use, inputs and
quality of care will also be explored. Data collected from
mapping of patient-level hospital costing will be tabu-
lated and summarised to draw out lessons for a defini-
tive trial.
Discussion
Hip fractures are one of the biggest challenges in the
medical community, giving rise to an estimated financial
burden in the UK alone of over £2 billion per annum
[3]. This study will examine the feasibility, acceptability
and economic consequences of a complex intervention
aiming to optimise care delivery to older patients with
hip fracture experiencing confusion. The study’s findings
will be used to build evidence to propose a definitive
evaluation of the intervention through a large-scale
pragmatic RCT.
We have used the term “confusion” in order to reflect
the real-world complexity of the acute hospital environ-
ment into which PERFECT-ER will be introduced.
Informed by clinical knowledge and learning from the
previous stages of our research, we note that PERFECT-
ER may improve care delivery to patients with presumed
dementia and other cognitive impairments such as delir-
ium. For PERFECT-ER to make a positive impact on the
care of older confused adults, it needs a broad approach.
The majority of patients admitted with hip fracture who
are experiencing confusion do not arrive with a con-
firmed dementia diagnosis. We will include confused
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patients (with known or presumed dementia and/or de-
lirium and/or cognitive impairment(s)) of any severity,
who incur a fractured hip, admitted from any setting.
Presence of dementia and sub-type of dementia will be
defined from medical notes at time-1 follow up.
The target patient group does present practical and
operational challenges, particularly for gaining consent
and accessing patients during follow up at their place of
residence. Given the cognitive impairment of the patient
participants, some outcome measures must be com-
pleted by proxy using suitable informants. We can
anticipate a number of challenges. It may be difficult to
locate suitable informants in a timely manner and to
maintain contact with them over the follow-up period.
An informant might be providing substantial support to
a confused older person with hip fracture and could feel
disinclined to participate in the research. Significant
challenges to both evaluation and implementation may
arise. The nature of the intervention is complex and the
acute hospital ward environment into which PERFECT-
ER will be introduced is high-pressured and ever-
changing. Such challenges provide additional justification
for the current feasibility study and multimethod, multi-
perspective process evaluation. The findings will inform
the development of a future large-scale pragmatic defini-
tive RCT and help to guide the worldwide delivery of care
to older patients experiencing hip fracture and confusion.
Findings will be published in high-quality academic jour-
nals and at high-impact academic conferences. Dissemin-
ation to clinical and service user stakeholders will take
many forms; these include via the programme’s social
media channels and website and the investigators’ net-
works including those with local and national user groups.
Trial status
This trial is currently ongoing and open to recruitment.
Recruitment began on 21 November 2016 and will close
on 31 January 2018.
Additional files
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